文献速递眼底病与葡萄膜炎

若干常见遗传变异与黄斑水肿抗VEGF治疗的功能或解剖学效应相关

Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

本研究对三项随机临床试验中606例接受贝伐珠单抗或雷珠单抗治疗的黄斑水肿患者进行全基因组关联研究(GWAS)荟萃分析,涵盖糖尿病性黄斑水肿、视网膜静脉阻塞和新生血管性年龄相关性黄斑变性。研究发现12个SNP(P<1×10^-6)与治疗6个月后中央亚区厚度变化相关,其中3个达全基因组显著性(P<5×10^-8);SGCZ基因位点与最佳矫正视力变化相关,KDR、IL6、NRP1、SPNS2变异与视力变化相关,PLVAP与中央亚区厚度变化相关。

要点

  • GWAS荟萃分析发现12个SNP(P<1×10^-6)与抗VEGF治疗6个月后CST变化相关,其中3个达全基因组显著性(P<5×10^-8)。
  • SGCZ基因位点与BCVA变化相关,KDR、IL6、NRP1、SPNS2变异与BCVA变化显著相关。
  • PLVAP基因与CST变化相关,该基因参与血管高通透性。

核心结论

  • 本GWAS荟萃分析发现了一些可能与伴有血管渗漏和/或黄斑水肿的视网膜疾病患者抗VEGF治疗反应相关的遗传变异。
  • 这些发现可能有助于识别用于预测治疗反应的遗传标志物,或揭示与视网膜血管渗漏和黄斑水肿相关的新通路。

研究设计与样本

  • 研究对来自三项随机临床试验的606例接受贝伐珠单抗或雷珠单抗治疗的黄斑水肿患者进行了全基因组关联研究(GWAS),使用Infinium Global Screening Array芯片。
  • 患者组包括糖尿病性黄斑水肿(DME)、视网膜静脉阻塞(RVO)和新生血管性年龄相关性黄斑变性(nAMD),结局指标为最佳矫正视力(BCVA)变化和中央亚区厚度(CST)解剖学变化。
  • 研究对合并患者组进行了荟萃分析,并对28个既往报道的抗VEGF反应相关遗传变异以及参与黄斑水肿病理生理的6个基因的变异进行了靶向分析。

主要发现

  • GWAS荟萃分析识别出12个SNP(P<1×10^-6),其中3个SNP达到全基因组显著性(P<5×10^-8),与抗VEGF治疗6个月后CST变化相关。
  • SGCZ基因中的一个基因组位点与BCVA变化相关。
  • 靶向GWAS显示BCVA变化与KDR、IL6、NRP1和SPNS2的变异之间存在显著关联,这些基因均已知在VEGF信号传导和视网膜血管通透性中发挥作用。
  • CST变化与PLVAP相关,PLVAP是黄斑水肿中血管高通透性的一个重要基因。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to identify genetic factors that may influence the effectiveness of anti-vascular endothelial growth factor (VEGF) treatment for macular edema (ME). METHODS: We performed a genome-wide association study (GWAS) on 606 patients with macular edema that were treated with bevacizumab or ranibizumab from three randomized clinical trials, using a Infinium Global Screening Array. Well-characterized patient groups included diabetic macular edema (DME), retinal vein occlusion (RVO), and neovascular age-related macular degeneration (nAMD), with changes in best-corrected visual acuity (BCVA) and anatomical changes in central subfield thickness (CST) as outcomes. We conducted a meta-analysis on the combined patient groups, a targeted analysis on 28 previously reported genetic variants related to anti-VEGF response, and on variants of six genes involved in ME pathophysiology. RESULTS: GWAS meta-analysis identified 12 SNPs (P < 1 × 10-6), of which three SNPs reached genome-wide significance (P < 5 × 10-8) and were linked to changes in CST after 6 months of anti-VEGF treatment. In addition, a genomic locus in the SGCZ gene was linked to changes in BCVA. Targeted GWAS revealed significant associations between changes in BCVA and variants in KDR, IL6, NRP1, and SPNS2, all known for their roles in VEGF signaling and retinal vascular permeability. Furthermore, changes in CST were associated with PLVAP, an important gene in vascular hyperpermeability in ME. CONCLUSIONS: This GWAS meta-analysis uncovered genetic variants potentially linked to responses to anti-VEGF treatment in patients with retinal conditions featuring vascular leakage and/or ME. These findings could aid in identifying genetic markers for treatment response prediction or uncover new pathways relevant to retinal vascular leakage and ME.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Klaassen I, Vader MJC, Aissa K, et al. Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema. Invest Ophthalmol Vis Sci. 2025. PMID: 40455044. doi:10.1167/iovs.66.6.2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。